VYNE Therapeutics Shares to Reverse Split on Monday, July 27th (NASDAQ:VYNE)

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) are set to reverse split on the morning of Monday, July 27th. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 26th.

VYNE Therapeutics Price Performance

NASDAQ:VYNE opened at $0.90 on Thursday. The firm’s 50-day moving average price is $0.68 and its 200-day moving average price is $0.63. The company has a market capitalization of $29.96 million, a PE ratio of -2.36 and a beta of 2.00. VYNE Therapeutics has a 1-year low of $0.28 and a 1-year high of $1.59.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.10. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.20 million. Equities analysts anticipate that VYNE Therapeutics will post -1.1 EPS for the current fiscal year.

VYNE Therapeutics Dividend Announcement

The firm also recently announced a special dividend, which will be paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd will be paid a dividend of $0.38 per share.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, VYNE Therapeutics currently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Anson Funds Management LP purchased a new position in VYNE Therapeutics in the 4th quarter worth approximately $739,000. ADAR1 Capital Management LLC boosted its stake in VYNE Therapeutics by 319.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock valued at $636,000 after purchasing an additional 810,108 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter worth $580,000. T3 Companies LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter worth $548,000. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares during the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.